https://www.hsph.harvard.edu/news/press-releases/dolutegravir-antiretroviral-hiv-pregnancy/
0
0
9/1/22 at 10:20pm
Organization
Harvard School of Engineering and Applied Sciences
38 words
0
Comments
For immediate release: September 1, 2022 Boston, MA— Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in…
You are the first to view
Create an account
or login to join the discussion